Verrica Pharmaceuticals Inc Stock News

– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH ® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatolog...

WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Globa...

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jayson M. Rieger - President, CEO & Director John J.

–   Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1'25 and $8.0 million in milestone revenue from Torii Pharmaceutical –

WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for ...

– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH ® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts – WEST CHESTER, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc....

– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule –

WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Co...